Centre of Excellence in Nutraceuticals inaugurated by the Hon’ble Chief Minister of Kerala

T’puram: Chief minister Pinarayi Vijayan virtually inaugurated a centre of excellence in nutraceuticals (CoEN) at Bio 360 Life Sciences Park, Thonnakkal, on Monday.

The initiative, spearheaded by Kerala State Council for Science, Technology and Environment (KSCSTE), with support from Kerala Development and Innovation Strategic Council (K-DISC) and Kerala State Industrial Development Corporation (KSIDC) and financial assistance from KIIFB, aims to position state as a leading hub for research and innovation in the rapidly expanding nutraceutical sector.

In his address, Vijayan highlighted the growing global relevance of nutraceuticals in addressing modern health challenges. “Bioactive compounds derived from food play an important role in enhancing immunity, preventing diseases and managing chronic conditions. The establishment of a centre of excellence in nutraceuticals marks a significant milestone in Kerala’s efforts to advance science-based preventive healthcare,” he said.

The centre began functioning at the campus of Institute of Advanced Virology (IAV) within Bio 360 Life Sciences Park and was allotted 5 acres for developing its dedicated infrastructure. The project will be implemented in phases, with Rs 13.99 crore sanctioned by KIIFB over a 5-year period.

Presenting the institutional roadmap, E Sreekumar, chief executive officer of CoEN, said Phase 1 will focus on research, technology development and scientific validation of nutraceutical formulations, particularly in areas related to metabolic health and wellness. Phase 2 will establish an enterprise division to facilitate manufacturing, technology transfer and commercialisation of research outcomes in collaboration with industry.

In the keynote address, C Anantharamakrishnan, director of CSIR–NIIST, hailed Kerala govt for its proactive initiatives in promoting science, research and innovation, noting that such efforts are crucial for strengthening the state’s emerging bioeconomy and nutraceutical sector.

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre